Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective
Feby Savira, Bing H Wang, Andrew R Kompa, Zanfina Ademi, Alice J Owen, Sophia Zoungas, Andrew Tonkin, Danny Liew, Ella Zomer
European Journal of Preventive Cardiology | SAGE PUBLICATIONS LTD | Published : 2020
AIM: To assess the cost-effectiveness of dapagliflozin in addition to standard care versus standard care alone in patients with chronic heart failure and reduced ejection fraction. METHODS: A Markov model was constructed based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial to assess the clinical outcomes and costs of 1000 hypothetical subjects with established heart failure and reduced ejection fraction. The model consisted of three health states: 'alive and event-free', 'alive after non-fatal hospitalisation for heart failure' and 'dead'. Costs and utilities were estimated from published sources. The main outcome was the incremental cost-effectiveness ratio p..View full abstract
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: FS is supported by a Monash International Postgraduate Research Scholarship and Monash Graduate Scholarship. The remaining authors received no financial support for the research, authorship, and/or publication of this article.